Search research articles
Contact Us
Filters
Showing results (301-310 of 444) with videos related to
Page
of 45
Sort By:
Frontiers in Oncology
|
March 28, 2019
Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor (<i>EGFR</i>)-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A California Cancer Consortium Phase II Trial (NCI 9303)
Karen L Reckamp, Paul H Frankel, Nora Ruel, et al.
Global Change Biology
|
August 4, 2025
A Meta-Regression of 18 Wildfire Chronosequences Reveals Key Environmental Drivers and Knowledge Gaps in the Boreal Nitrogen Balance
Stefan F Hupperts, Frank Berninger, Han Y H Chen, et al.
Cancer Chemotherapy and Pharmacology
|
January 27, 2009
A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer
Ramesh K Ramanathan, Chandra P Belani, Deepti A Singh, et al.
International Journal of Radiation Oncology, Biology, Physics
|
October 20, 2001
Radiation Therapy Oncology Group. Research Plan 2002-2006. Head and Neck Cancer Committee
K Ang, R Weber, E Vokes, et al.
Cancer Treatment and Research Communications
|
July 13, 2019
Bone turnover biomarkers identify unique prognostic risk groups in men with castration resistant prostate cancer and skeletal metastases: Results from SWOG S0421
P N Lara, M Plets, C Tangen, et al.
The Oncologist
|
March 17, 2022
Targeted Next-Generation Sequencing Reveals Exceptionally High Rates of Molecular Driver Mutations in Never-Smokers With Lung Adenocarcinoma
Philip C Mack, Michael I Klein, Kristin L Ayers, et al.
Cancer Chemotherapy and Pharmacology
|
August 8, 2001
Activity of high-dose toremifene plus cisplatin in platinum-treated non-small-cell lung cancer: a phase II California Cancer Consortium Trial
P N Lara, D R Gandara, J Longmate, et al.
The Journal of Clinical Investigation
|
June 21, 2016
RBPJ maintains brain tumor-initiating cells through CDK9-mediated transcriptional elongation
Qi Xie, Qiulian Wu, Leo Kim, et al.
Lung Cancer (Amsterdam, Netherlands)
|
December 17, 2013
KRAS mutations in non-small-cell lung cancer and colorectal cancer: implications for EGFR-targeted therapies
M K H Maus, P P Grimminger, P C Mack, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 14, 2019
SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway-Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy)
Charu Aggarwal, Mary W Redman, Primo N Lara, et al.
Page
of 45
Search research articles
Search
Showing results (301-310 of 444) with videos related to
Sort By:
Page
of 45
Frontiers in Oncology
|
March 28, 2019
Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor (<i>EGFR</i>)-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A California Cancer Consortium Phase II Trial (NCI 9303)
Karen L Reckamp, Paul H Frankel, Nora Ruel, et al.
Global Change Biology
|
August 4, 2025
A Meta-Regression of 18 Wildfire Chronosequences Reveals Key Environmental Drivers and Knowledge Gaps in the Boreal Nitrogen Balance
Stefan F Hupperts, Frank Berninger, Han Y H Chen, et al.
Cancer Chemotherapy and Pharmacology
|
January 27, 2009
A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer
Ramesh K Ramanathan, Chandra P Belani, Deepti A Singh, et al.
International Journal of Radiation Oncology, Biology, Physics
|
October 20, 2001
Radiation Therapy Oncology Group. Research Plan 2002-2006. Head and Neck Cancer Committee
K Ang, R Weber, E Vokes, et al.
Cancer Treatment and Research Communications
|
July 13, 2019
Bone turnover biomarkers identify unique prognostic risk groups in men with castration resistant prostate cancer and skeletal metastases: Results from SWOG S0421
P N Lara, M Plets, C Tangen, et al.
The Oncologist
|
March 17, 2022
Targeted Next-Generation Sequencing Reveals Exceptionally High Rates of Molecular Driver Mutations in Never-Smokers With Lung Adenocarcinoma
Philip C Mack, Michael I Klein, Kristin L Ayers, et al.
Cancer Chemotherapy and Pharmacology
|
August 8, 2001
Activity of high-dose toremifene plus cisplatin in platinum-treated non-small-cell lung cancer: a phase II California Cancer Consortium Trial
P N Lara, D R Gandara, J Longmate, et al.
The Journal of Clinical Investigation
|
June 21, 2016
RBPJ maintains brain tumor-initiating cells through CDK9-mediated transcriptional elongation
Qi Xie, Qiulian Wu, Leo Kim, et al.
Lung Cancer (Amsterdam, Netherlands)
|
December 17, 2013
KRAS mutations in non-small-cell lung cancer and colorectal cancer: implications for EGFR-targeted therapies
M K H Maus, P P Grimminger, P C Mack, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 14, 2019
SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway-Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy)
Charu Aggarwal, Mary W Redman, Primo N Lara, et al.
Page
of 45